期刊
EXPERIMENTAL BIOLOGY AND MEDICINE
卷 235, 期 1, 页码 3-9出版社
SAGE PUBLICATIONS LTD
DOI: 10.1258/ebm.2009.009191
关键词
lung cancer; angiogenesis; VEGF; antiangiogenesis
资金
- Randall Bridwell Lung Cancer Research
- Effie Marie Cain Scholarship in Angiogenesis Research
- NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER
Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据